Visceral fat, the deep abdominal fat surrounding vital organs, is a major health concern linked to metabolic disorders, cardiovascular diseases, and insulin resistance. Many individuals struggling with obesity seek medical interventions to target this stubborn fat. One such treatment gaining attention is the use of Ozempic injections, a medication primarily prescribed for type 2 diabetes. While Ozempic 1 mg price in Dubai may vary, its effectiveness in reducing visceral fat has become a topic of significant interest among researchers and healthcare professionals.
Visceral fat differs from subcutaneous fat, which lies just beneath the skin. Unlike subcutaneous fat, visceral fat accumulates around internal organs such as the liver, pancreas, and intestines. High levels of this fat are associated with serious health conditions, including:
Because visceral fat is metabolically active, it releases inflammatory cytokines and free fatty acids, further exacerbating health risks. Traditional weight loss methods, such as diet and exercise, may not always effectively target this fat, leading many to explore pharmaceutical options like Ozempic.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Originally developed to manage blood sugar levels in type 2 diabetes, it has also shown promise in promoting weight loss. The medication works by:
These mechanisms contribute to gradual weight loss, which may include reductions in visceral fat.
Several clinical studies have examined Ozempic’s impact on body composition, particularly visceral fat.
A 2021 study published in The New England Journal of Medicine investigated semaglutide’s effects on weight loss in non-diabetic obese individuals. Participants receiving a 2.4 mg dose (higher than the standard diabetes dose) experienced an average 15% reduction in body weight, with significant decreases in visceral fat measured via MRI scans.